Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kuznar W - Dutasteride (Avodart) reduces the risk of biopsy-detectable prostate cancer by about one-fourth in men at high risk for the disease without increasing the risk of high-grade cancers. In addition, the 5-alpha-reductase inhibitor significantly enhances the utility of PSA as a diagnostic test for prostate cancer. In men assigned to dutasteride, the number of positive cores was lower for all tumors, including high-grade tumors, and the proportion of cores involved with cancer was lower, including the high-grade tumors.


Today in Hematology/Oncology...keeping you current

Approach to Thrombocytopenia in Older Adults
Geriatrics & Aging, 11/10/09

Update on oral lichen planus
Expert Review of Dermatology, 10/14/09

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
Thyroid, 10/30/09

Today in Nephrology/Urology...keeping you current

Systematic Review: Sodium Bicarbonate Treatment Regimens for the Prevention of Contrast-Induced Nephropathy
Annals of Internal Medicine, 11/03/09

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Kidney International, 11/05/09

Managing diabetes in hemodialysis patients: Observations and recommendations
Cleveland Clinic Journal of Medicine, 11/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address